```

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    ---------
                                    FORM 10-Q
                                    ---------

(Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
     ACT OF 1934

                  For the six months period ended June 30, 2009

                                       OR

[_]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
     EXCHANGE ACT OF 1934

             For the transition period from _________ to __________

                        Commission File Number: 000-17788

                              NEXGEN BIOFUELS LTD.
            (EXACT NAME OF REGISTRANTS AS SPECIFIED IN ITS CHARTERS)

                 ISRAEL                                           N/A
    (STATE OR OTHER JURISDICTION OF                         (I.R.S. EMPLOYER
     INCORPORATION OR ORGANIZATION)                       IDENTIFICATION NO.)

   8909 REGENTS PARK DRIVE, SUITE 210                            33547
             TAMPA, FLORIDA
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICE)                       (ZIP CODE)

                                 (813) 293-3534
              (REGISTRANTS' TELEPHONE NUMBER, INCLUDING AREA CODE)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                               Yes [X]     No [_]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer' and "smaller
reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

      Large accelerated filer [_]                      Accelerated filer [_]

       Non-accelerated filer [_]                   Smaller reporting company [X]

     Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).

                               Yes [_]     No [X]

Indicate the number of shares outstanding of each class of Ordinary Shares, as
of the latest practicable date

               CLASS                           OUTSTANDING AS OF AUGUST 4, 2008
-----------------------------------           ----------------------------------
Ordinary Shares, NIS 0.04 Par Value                   42,730,198 Shares
```

```

                              NEXGEN BIOFUELS LTD.
                                    FORM 10-Q

                                QUARTERLY REPORT

                                TABLE OF CONTENTS

           Consolidated Financial Statements

           Consolidated Balance Sheets - June 30, 2009 and December 31, 2008                          3-4

           Consolidated Statements of Operations - Six months and Three-month periods
           ended June 30, 2009 and 2008, and from August 10, 2006 (inception) to June 30,
           2009 (unaudited)                                                                             5

           Consolidated Statements of Cash Flows - For the Six months ended June 30, 2009
           and 2008 and from August 10, 2006 (inception) to June 30, 2009                               6

           Notes to Consolidated Financial Statements                                                7-15

Item 1.    Investment in Land Purchase Options                                                         15

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of
           Operations                                                                                  15

Item 3.    Controls and Procedures                                                                     18

                                       2
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED BALANCE SHEETS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

                                                   JUNE 30,       DECEMBER 31,
                                                   2 0 0 9          2 0 0 8
                                                 ------------    ------------
                                                  UNAUDITED         AUDITED
                                                 ------------    ------------

ASSETS

CURRENT ASSETS
   Cash and cash equivalents                                2               4
                                                 ------------    ------------

LONG-TERM INVESTMENTS
   Investments in land purchase options                    21              84
                                                 ------------    ------------

PROPERTY AND EQUIPMENT, NET                                 5               5
                                                 ------------    ------------

   Total Assets                                            28              93
                                                 ============    ============

   The accompanying notes to these financial statements are an integral part
                                    thereof.

                                       3
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED BALANCE SHEETS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS (EXCEPT SHARE DATA)

                                                                                JUNE 30,       DECEMBER 31,
                                                                                2 0 0 9          2 0 0 8
                                                                              ------------     ------------
                                                                                UNAUDITED         AUDITED
                                                                              ------------     ------------

LIABILITIES AND SHAREHOLDERS' DEFICIT

CURRENT LIABILITIES
Credits from related parties                                                           901              807
   Trade payables                                                                      238              217
   Other accounts payables                                                              12               13
                                                                              ------------     ------------
    Total current liabilities                                                        1,151            1,037
                                                                              ------------     ------------

SHAREHOLDERS' DEFICIT
Share capital
   Ordinary shares NIS 0.04 par value - Authorized 1,900,000,000
     shares as of June 30, 2009 and December 31, 2008;
   Issued and  outstanding: 42,730,998 shares as of June 30,
     2009 and December 31, 2008                                                        445              445
   Additional paid-in capital                                                        2,665            2,665
   Accumulated deficit                                                              (4,233)          (4,054)
                                                                              ------------     ------------
   Total shareholders' deficit                                                      (1,123)            (944)
                                                                              ------------     ------------

   Total liabilities and shareholders' deficit                                          28               93
                                                                              ============     ============

   The accompanying notes to these financial statements are an integral part
                                    thereof.

            August 11, 2009
--------------------------------------------       -----------------------------
Date of Approval of the Financial Statements                Director

                                       4
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

                                                                                                 AUGUST 10, 2006
                                              THREE MONTHS ENDED           SIX MONTHS ENDED        (INCEPTION)
                                                   JUNE 30,                    JUNE 30,          THROUGH JUNE 30,
                                              2009          2008          2009          2008         2 0 0 9
                                           ----------    ----------    ----------    ----------    ----------
                                                  UNAUDITED                   UNAUDITED            UNAUDITED
                                           ------------------------    ------------------------    ----------

EXPENSES:
Legal and professional                             17           138            28           361         1,001
Salaries                                          -.-           115            83           271         1,189
Travel                                            -.-            24             3            95           394
Loss from expiration of land purchase
option and futures trading                        -.-            20            63            20           294
Compensation on shares issuance and
options                                           -.-            59           -.-           534           621
Other expenses                                      2            38             2           111           654
                                           ----------    ----------    ----------    ----------    ----------

Net loss from operations                           19           394           179         1,392         4,153

Interest expense                                  -.-             4           -.-             7            84
Capital gain                                      -.-           -.-           -.-           -.-            (4)
                                           ----------    ----------    ----------    ----------    ----------

NET LOSS                                           19           398           179         1,399         4,233
                                           ----------    ----------    ----------    ----------    ----------

Basic and diluted loss per share
                                                0.004          0.01         0.004          0.03           0.1
                                           ==========    ==========    ==========    ==========    ==========

Weighted average number of shares used
in computing basic and diluted loss
per share attributed to Ordinary
shareholders
                                           42,730,998    42,730,998    42,730,998    42,730,998    36,247,555
                                           ==========    ==========    ==========    ==========    ==========

   The accompanying notes to these financial statements are an integral part
                                    thereof.

                                       5
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF CASH FLOWS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

                                                                         AUGUST 10, 2006
                                                  SIX MONTHS ENDED     (DATE OF INCEPTION)
                                               JUNE 30,      JUNE 30,      TO JUNE 30,
                                                 2009          2008           2009
                                              ----------    ----------     ----------
                                                      UNAUDITED             UNAUDITED
                                              ------------------------     ----------

OPERATING ACTIVITIES
 Net loss                                           (179)       (1,399)        (4,233)
 Adjustments to reconcile net loss to net
   cash used in operating activities:
 Depreciation expenses                               -.-           -.-              1
 Compensation related to share and option
   issuance to employees                             -.-           533            577
 Expiration of land purchase option and
   futures trading                                    63            20            219
 Issuance of shares                                  -.-           -.-            187
 Increase (decrease) in other receivables            -.-           (19)             5
 Increase (decrease) in trade payables                21          (146)           349
 Increase (decrease)  in other accounts
   payables                                           (1)          (36)           458
                                              ----------    ----------     ----------

 Net cash used in operating activities               (96)       (1,047)        (2,437)
                                              ----------    ----------     ----------

INVESTING ACTIVITIES
 Purchase of computer equipment                      -.-           -.-             (4)
 Cash used in connection with acquisition            -.-           -.-           (280)
 Repayment of Gamida For Life B.V. debt              -.-           397            397
 Repayment of loan to Gamidor Diagnostics            -.-          (230)          (230)
 Investments in land purchase options and
   futures trading                                   -.-           -.-           (193)
                                              ----------    ----------     ----------

 Net cash provided by (used in) investing
   activities                                        -.-           167           (310)
                                              ----------    ----------     ----------

FINANCING ACTIVITIES
 Credit from related party                            94           476          2,415
 Repayment of short term bank credit                 -.-           (35)           (39)
 Purchase of treasury shares                         -.-           -.-            (68)
 Proceeds from issuance of shares                    -.-           440            441
                                              ----------    ----------     ----------

 Net cash provided by financing activities            94           881          2,749
                                              ----------    ----------     ----------

 NET INCREASE (DECREASE) IN CASH                      (2)            1              2
 CASH AT BEGINNING OF PERIOD                           4             1            -.-
                                              ----------    ----------     ----------

 CASH AT END OF PERIOD                                 2             2              2
                                              ==========    ==========     ==========

   The accompanying notes are an integral part of the consolidated financial
                                  statements.

                                       6
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION

     a.   General

          NexGen Biofuels Ltd. (formally: Healthcare Technologies Ltd.) and its
          subsidiaries (the "Company" or "NexGen"), is a development stage
          company that is currently seeking to green develop and/or acquire
          blending terminal facilities and, ethanol and bio-diesel plants in the
          United States.

          NexGen Biofuels Ltd. was established as an Israeli corporation. Prior
          to closing of the Purchase Agreement on December 31, 2007, the
          Company's business was in the field of diagnostic and biotech. In
          accordance with the Purchase Agreement, dated January 16, 2007, as
          amended (the "Purchase Agreement"), and consummated on December 31,
          2007, by and among, the Company, NexGen Biofuels, Inc., ("NexGen
          Bio"), MAC Bioventures Inc., ("MAC"), the parent company of NexGen
          Bio, and Gamida for Life B.V., ("Gamida"), the parent company of
          NexGen, the Company completed a Plan of Arrangement (the "Plan") as
          following:

          1.   The Company transferred substantially all of its existing assets
               and liabilities to Gamida, in consideration for 4,700,000 shares
               of the Company held by Gamida.

          2.   NexGen Bio transferred its principal assets (the "NexGen Assets")
               in the ethanol and biodiesel fuel industry consisting of options
               to purchase five Greenfield sites in the United States and
               permitting for 100 million gallons of annual ethanol or
               bio-diesel production capacity per site to NexGen 2007, Inc
               ("NewCo"), a wholly-owned subsidiary of the Company;

          3.   The Company issued to MAC and MAC's designees an aggregate of
               38,280,000 ordinary shares, representing the $58 million
               appraised value of the NexGen Assets divided by $1.50 (the agreed
               upon value of NexGen share) less 1%; In addition, the Company
               issued 386,666 ordinary shares to one of its directors. see also
               note 2a.

          The Plan was approved by the shareholders approval on December 4,
          2007.

          Prior to the Plan, the Company had no substantial operations as it had
          transferred all of its existing assets to Gamida. Therefore, the
          financial statements and accompanying notes represent the historical
          results of NexGen Bio, unless otherwise stated.

          On January 28, 2008, the Company changed its name from Healthcare
          Technologies Ltd. to NexGen Biofuels Ltd.

                                       7
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION (CONT.)

     b.   Development Stage Enterprise

          The Company has been in the development stage since its formation on
          August 10, 2006. It has primarily been engaged in the development of
          blending terminals and ethanol/biodiesel plants while raising capital
          to carry out its business plan. The Company expects to continue to
          incur significant operating losses and to generate negative cash flow
          from operating activities while it develops projects, its customer
          base and establishes itself in the marketplace. The Company's ability
          to eliminate operating losses and to generate positive cash flow from
          operations in the future will depend upon a variety of factors, many
          of which the Company may be unable to control. If the Company is
          unable to implement its business plan successfully, it may not be able
          to eliminate operating losses, generate positive cash flow, or achieve
          or sustain profitability, which would materially adversely affect its
          business, operations, and financial results, as well as its ability to
          make payments on its debt obligations.

     c.   Going Concern

          The Company incurred a net loss of $ 4,233 thousand for the period
          August 10, 2006 (inception) through June 30, 2009. As of June 30, 2009
          the Company had $ 1,149 thousand of negative working capital, a
          deficit of $ 1,123 thousand and $ 2 thousand of cash. The Company
          depends upon capital to be derived from future financial activities,
          such as future offerings of its Ordinary Shares, or debt financing in
          order to operate and increase or expand the business. There can be no
          assurance that the Company will be successful in raising such capital.
          The key factors that are not within the Company's control and that
          have a direct bearing on operating results include, but are not
          limited to, acceptance of the Company's business plan, the ability to
          raise capital in the future, the ability to expand its customer base,
          and the ability to hire key employees to increase or expand the
          business. There may be other risks and circumstances that management
          may be unable to predict. These conditions raise substantial doubt
          about the Company's ability to continue as a going concern. The
          accompanying consolidated financial statements do not include any
          adjustments relating to recoverability of assets and classification of
          liabilities that might be necessary should the Company be unable to
          continue as a going concern.

                                       8
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION (CONT.)

     d.   Basis of Presentation-Interim Financial Statements

          The accompanying unaudited interim consolidated financial statements
          and related notes have been prepared in accordance with accounting
          principles generally accepted in the United States of America for
          interim financial information and the instructions to Form 10-Q and
          Rule 10-01 of Regulation S-X. Accordingly, they do not include all of
          the information and footnotes required by generally accepted
          accounting principles for complete financial statements. Results for
          interim periods should not be considered indicative of results for a
          full year. These interim consolidated financial statements should be
          read in conjunction with the consolidated financial statements and
          related notes contained in the Company's Annual Report on Form 10-K
          for the year ended December 31, 2008. Except as disclosed in Note 1e
          below, the accounting policies used in preparing these consolidated
          financial statements are the same as those described in the
          consolidated financial statements in the Company's Annual Report on
          Form 10-K for the year ended December 31, 2008. Filed April 15, 2009.

          In the opinion of management, all adjustments (consisting of normal
          recurring adjustments) considered necessary for a fair statement of
          the results for interim periods have been included. All significant
          intercompany accounts and transactions have been eliminated in
          consolidation.

          The preparation of financial statements in conformity with generally
          accepted accounting principles requires management to make estimates
          and assumptions that affect the amounts reported in the financial
          statements and accompanying notes. Actual results could differ from
          those estimates.

                                       9
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION (CONT.)

     e.   RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

          SFAS 157 - FAIR VALUE MEASUREMENT:

          In September 2006, the FASB issued SFAS No. 157, "Fair Value
          Measurements ("FAS 157"). This standard defines fair value,
          establishes a framework and gives guidance regarding the methods used
          for measuring fair value, and expands disclosures about fair value
          measurements. This standard is in effect for financial statements
          issued for fiscal years beginning after November 15, 2007. In February
          2008, the FASB released a FASB Staff Position (FSP FAS 157-2-
          Effective Date of FASB Statement No. 157) which delays the effective
          date of SFAS No. 157 for all non-financial assets and non-financial
          liabilities, except those that are recognized or disclosed at fair
          value in the financial statements on a recurring basis (at least
          annually) to fiscal years beginning after November 15, 2008. The
          company believes that the adoption of SFAS No. 157 will not have an
          impact on the Company's financial position or results of operations.

          SFAS 159- THE FAIR VALUE OPTION FOR FINANCIAL ASSETS AND LIABILITIES:

          In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option
          for Financial Assets and Financial Liabilities - Including an
          amendment of FASB Statement No. 115," which provides a fair value
          option election that permits entities to irrevocably elect to measure
          certain financial assets and liabilities (exceptions are specifically
          identified in the Statement) at fair value as the initial and
          subsequent measurement attribute, with changes in fair value
          recognized in earnings as they occur. SFAS No. 159 permits the fair
          value option election on an instrument-by-instrument basis at initial
          recognition of an asset or liability or upon an event that gives rise
          to a new basis of accounting for that instrument. The adoption of SFAS
          No. 159 on January 1, 2008, for financial assets and liabilities did
          not have an impact on the Company's financial position or results of
          operations.

                                       10
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION (CONT.)

     SFAS NO. 141(REVISED 2007): BUSINESS COMBINATIONS ("SFAS NO. 141(R)") AND
     SFAS NO. 160: NONCONTROLLING INTERESTS IN CONSOLIDATED FINANCIAL
     STATEMENTS, AN AMENDMENT OF ARB NO. 51 ("SFAS NO. 160"):

     In December 2007, the FASB issued SFAS No. 141(R) and SFAS No. 160. SFAS
     No. 141(R) will significantly change how business acquisitions are
     accounted for at the acquisition date and in subsequent periods. The
     standard changes the accounting for the business combination at the
     acquisition date to a fair value based approach rather than the cost
     allocation approach currently used. Other differences include changes in
     the accounting for acquisition related costs, contingencies and income
     taxes. SFAS No. 160 changes the accounting and reporting for minority
     interests, which will be classified as a component of equity and will be
     referred to as noncontrolling interests.

     SFAS No. 141(R) and SFAS No. 160 will be effective for public companies for
     fiscal years beginning on or after December 15, 2008. SFAS No. 141(R) and
     SFAS No. 160 will be applied prospectively, except for the presentation and
     disclosure requirements in SFAS No. 160 for existing minority interests
     which will require retroactive adoption. Early adoption is prohibited. SFAS
     No. 141(R) and SFAS No. 160 are not applicable for the company.

     The adoption did not have an impact on the Company's results of operations
     or financial condition.

     SFAS NO. 161 "DISCLOSURES ABOUT DERIVATIVE INSTRUMENTS AND HEDGING
     ACTIVITIES" ("SFAS NO. 161"):

     In March 2008, the FASB issued SFAS No. 161 "Disclosures about Derivative
     Instruments and Hedging Activities" ("SFAS No. 161"), which will require
     increased disclosures about an entity's strategies and objectives for using
     derivative instruments; the location and amounts of derivative instruments
     in an entity's financial statements; how derivative instruments and related
     hedged items are accounted for under SFAS No. 133, and how derivative
     instruments and related hedged items affect its financial position,
     financial performance, and cash flows. Certain disclosures will also be
     required with respect to derivative features that are credit risk-related.
     SFAS No. 161 is effective for the Company beginning on January 1, 2009 on a
     prospective basis. The adoption did not have an impact on the Company's
     results of operations or financial condition.

     FSP NO. FAS 142-3: DETERMINATION OF THE USEFUL LIFE OF INTANGIBLE ASSETS
     ("FSP NO. FAS 142-3"):

     In April 2008, the FASB issued FSP No. FAS 142-3, which amends the factors
     considered in developing renewal or extension assumptions used to determine
     the useful life of a recognized intangible asset under SFAS No. 142. FSP
     No. 142-3 requires a consistent approach between the useful life of a
     recognized intangible asset under SFAS No. 142 and the period of expected
     cash flows used to measure the fair value of an asset under SFAS No.
     141(R).

                                       11
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION (CONT.)

     The FSP also requires enhanced disclosures when an intangible asset's
     expected future cash flows are affected by an entity's intent and/or
     ability to renew or extend the arrangement. FSP No. 142-3 is effective for
     financial statements issued for fiscal years beginning after December 15,
     2008, January 1, 2009 for the Company, and is to be applied prospectively.
     Early adoption is prohibited. The Company does not believe the adoption
     will have an impact on the Company's financial condition, results of
     operations, or cash flows.

     EITF 08-3: ACCOUNTING BY LESSEES FOR MAINTENANCE DEPOSITS ("EITF 08-3"):

     In June 2008, the Emerging Issues Task Force ("EITF") issued EITF 08-3,
     which clarifies how a lessee accounts for nonrefundable maintenance
     deposits. Under EITF 08-3, nonrefundable maintenance deposits will be
     recorded as a deposit asset and as reimbursable maintenance is performed by
     the lessee, the underlying maintenance is expensed or capitalized in
     accordance with the lessee's accounting policy. EITF 08-3 is in effect for
     the Company beginning on January 1, 2009. Early adoption is not permitted.
     The effect of adoption will be reflected as a change in accounting
     principle through a cumulative effect adjustment to the opening balance of
     retained earnings in the year of adoption. The adoption of EITF 08-3, did
     not have an impact on the Company's financial statements.

     FSP NO. 157-3: DETERMINING THE FAIR VALUE OF A FINANCIAL ASSET WHEN THE
     MARKET FOR THAT ASSET IS NOT ACTIVE ("FSP NO. 157-3"):

     In October 2008, the FASB issued FSP No. 157-3, which clarifies the
     application of SFAS No. 157 in a market that is not active and provides an
     example to illustrate key considerations in determining the fair value of a
     financial asset when the market for that financial asset is not active. The
     guidance emphasizes that determining fair value in an inactive market
     depends on the facts and circumstances and may require the use of
     significant judgments.

     FSP No. 157-3 is effective upon issuance, including prior periods for which
     financial statements have not been issued. The adoption of FSP No. 157-3
     did not have an impact on the Company.

                                       12
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 1:- ORGANIZATION AND BASIS OF PRESENTATION (CONT.)

     FSP NO. FAS 132(R)-1: EMPLOYERS' DISCLOSURES ABOUT POSTRETIREMENT BENEFIT
     PLAN ASSETS ("FSP NO. FAS 132(R)-1"):

     In December 2008, the FASB issued FSP No. FAS 132(R)-1, which provides
     guidance regarding an employer's disclosures about plan assets of a defined
     benefit pension or other postretirement plan. The FSP is effective for
     fiscal years ending after December 15, 2009, or the year ending December
     31, 2009 for the Company. The Company has reviewed FAS 132 (R) and
     determined is not applicable for the Company.

     FAS 115-2 AND FAS 124-2 - RECOGNITION AND PRESENTATION OF
     OTHER-THAN-TEMPORARY IMPAIRMENTS:

     In April 2009, the FASB Issued FAS No. 115-2 and FAS No. 124-2,
     "Recognition and Presentation of Other-Than-Temporary Impairments". This
     FSP amends the other-than-temporary impairment guidance for debt securities
     to make the guidance more operational and to improve the presentation and
     disclosure of other-than-temporary impairments in the financial statements.
     The most significant change the FSP brings is a revision to the amount of
     other-than-temporary loss of a debt security recorded in earnings. FSP FAS
     157-4 and FSP FAS 115-2/FAS 124-2 must be adopted at the same time.

     FSP FAS 115-2 and FAS 124-2 is in effect for interim and annual reporting
     periods ending after June 15, 2009, and it will have no impact on the
     Company's financial statements.

     FAS 157-4 - DETERMINING FAIR VALUE WHEN THE VOLUME AND LEVEL OF ACTIVITY
     FOR THE ASSET OR LIABILITY HAVE SIGNIFICANTLY DECREASED AND IDENTIFYING
     TRANSACTIONS THAT ARE NOT ORDERLY:

     In April 2009, the FASB Issued FAS No. 157-4, "Determining Fair Value When
     the Volume and Level of Activity for the Asset or Liability Have
     Significantly Decreased and Identifying Transactions That Are Not Orderly"

     This FASB Staff Position (FSP) provides additional guidance for estimating
     fair value in accordance with FASB Statement No. 157, FAIR VALUE
     MEASUREMENTS, when the volume and level of activity for the asset or
     liability have significantly decreased. This FSP also includes guidance on
     identifying circumstances that indicate a transaction is not orderly. FAS
     No. 157-4 is in effect for interim reporting periods ending after June 15,
     2009. The company believes that it will not have an impact on its financial
     statements.

                                       13
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 2 - COMMITMENTS AND CONTINGENT LIABILITIES

     Options

     a.   On January 9, 2008, the Company granted one of its executives 650,000
          options to purchase Ordinary shares of the Company under the ISO Plan.
          The Options have the following terms, among others: (i) a term of 5
          years, subject to earlier expiration; (ii) an exercise price of $1.50
          per share, and (iii) vesting and exercise rights in five annually
          equal installments of 130,000 shares each. The Company has accounted
          for these options in accordance with FAS123(R). The fair value of each
          option is estimated on the date of grant using a Black-Scholes option
          pricing model. As of June 1 2008, the employment agreement with the
          executive was terminated by mutual agreement. The total grant fair
          value recorded was $ 28 thousand.

          According to the Purchase Agreement, the Company granted to Israel
          Amir 386,666 Ordinary Shares for his willingness to commit to serve as
          a director of the Company for a period of no less than two years after
          the Closing. The Company has accounted for this grant in accordance
          with FAS123(R). The total grant date fair value was $ 352 thousand,
          reflecting the quoted market price of the Company's Ordinary shares as
          of the date of grant over the purchase price of $ 0 as compensation
          expense, ratably over the release two years period of the restricted
          shares. The agreement was terminated. The total grant fair value
          recorded was $176 thousand.

     b.   All directors of the Company, except one, have resigned. This
          situation does not meet the requirements of the Israeli Corporate law
          as to minimal number of directors required by a public company.

NOTE 3 - RELATED PARTY TRANSACTIONS

     During the six months ended June 30, 2009, the Company recorded related
     party salary in the amount of $ 83 thousand.

                                       14
```

```

NEXGEN BIOFUELS AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
--------------------------------------------------------------------------------
U.S. DOLLARS IN THOUSANDS

NOTE 4 - OTHER SIGNIFICANT CURRENT PERIOD EVENTS

     On March 29, 2009, the Company announced that it had signed a non-binding
     Letter of Intent with World Venture Management, Inc., a Nevada based
     company (hereinafter: "WVM") and Mac Bioventures, Inc. The transaction
     includes (i) the transfer to NexGen of WVM's assets relating to its real
     estate acquisitions and asset management enterprises, such as
     hotel/casinos, wineries and vineyards, refineries, office buildings and
     apartment complexes, shopping malls and other commercial buildings, in
     addition to the management of certain assets such as gemstones, gold and
     diamonds and in-ground assets such as coal and oil, gas and natural gas, in
     the United states in consideration for a controlling stake in NexGen and
     (ii) the purchase of NexGen's holdings in its subsidiaries by Mac
     Bioventures in consideration for a part of the debt it is assuming in
     NexGen. This agreement was further extended until August 31, 2009.

     The Letter of Intent further contemplates that the number of shares up to
     65 million to be issued in consideration for WVM's assets shall be based on
     the valuation of the assets to be provided by a recognized valuation firm.

     Closing of the transaction is subject to the negotiation and execution of
     definitive agreements, the completion of due diligence, the receipt of the
     necessary corporate, regulatory and third party approvals, including
     NexGen's shareholders and the approval of an Israeli District Court. No
     assurance can be given that a definitive agreement will be signed or that
     the transaction will close.

ITEM 1:- INVESTEMENTS IN LAND PURCHASE OPTIONS

     Due to the depressed state of the ethanol/biodiesel industry, coupled with
     lack of Greenfield project financing for ethanol/biodiesel projects, the
     Company will not extend any of the land options upon expiration.

ITEM 2:- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR RESULTS
OF OPERATIONS

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the "Report") of NexGen Biofuels Ltd., an
Israeli corporation (formerly known as Healthcare Technologies Ltd.) (the
"Company," "NexGen," "we," "us" and "our"), contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. This Report
includes statements regarding our plans, goals, strategies, intent, beliefs or
current expectations. These statements are expressed in good faith and based
upon a reasonable basis when made, but there can be no assurance that these
expectations will be achieved or accomplished. These forward looking statements
can be identified by the use of terms and phrases such as "believe," "plan,"
"intend," "anticipate," "target," "estimate," "expect," and the like, and/or
future-tense or conditional constructions ("will," "may," "could," "should,"
etc.). Items contemplating or making assumptions about, actual or potential
future sales, market size, collaborations, and trends or operating results also
constitute such forward-looking statements.

                                       15
```

```

Although forward-looking statements in this report reflect the good faith
judgment of management, forward-looking statements are inherently subject to
known and unknown risks, business, economic and other risks and uncertainties
that may cause actual results to be materially different from those discussed in
these forward-looking statements. Readers are urged not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
report. We assume no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the date of this
report, other than as may be required by applicable law or regulation. Readers
are urged to carefully review and consider the various disclosures made by us in
our reports filed with the Securities and Exchange Commission ("SEC") which
attempt to advise interested parties of the risks and factors that may affect
our business, financial condition, results of operation and cash flows,
including the in the field of ethanol and bio-diesel fuel production under "Risk
Factors" in Item 1A of our Annual Report on Form 10K for the fiscal year ended
December 31, 2007. If one or more of these risks or uncertainties materialize,
or if the underlying assumptions prove incorrect, our actual results may vary
materially from those expected or projected.

OVERVIEW

NexGen is currently in the process of seeking to raise capital to develop,
construct, and/or acquire, own, and operate ethanol and biodiesel blending
terminal facilities in the United States.

NexGen is pursuing a vertically integrated strategy involving the blending of
ethanol and biodiesel through developing/acquiring of blending terminal and
production facilities. The Company plans to build the blending terminal
following the receipt of phase-I financing.

In order to be responsive to changing market conditions in the ethanol and
bio-diesel industries, and in the capital markets, we intend to postpone our
plans to construct or and/or acquire ethanol and bio-diesel plants in favor of
developing a blending terminal first. Two non binding letters of intent
("LOI's") for purchase of the majority interest in two separate ethanol
production facilities expired during May 2008 and have not been renewed. The
Company intends to renegotiate those LOI's and/or consider other opportunities
to acquire or construct operating plants as soon as market conditions improve to
the point that conditions become favorable for such developments.

In NexGen's view, controlling assets at both ends of the ethanol and biodiesel
value chains offer a highly effective means for buffering the operating and
financial impacts caused by ethanol and biodiesel price volatility resulting
from feedstock and production output supply/demand imbalances.

GENERAL

In accordance with the Purchase Agreement, on December 31, 2007, the Company
completed the Plan pursuant to which the Company transferred substantially all
of its existing business and assets in the field of biotechnology and medical
devices to Gamida For Life B.V. and acquired NexGen Bio's principal assets in
the field of ethanol and bio-diesel fuel production.

The Plan was treated as a reverse merger of the Company for financial accounting
purposes. Accordingly, the historical financial statements of the Company before
the Plan will be replaced with the historical financial statements of NexGen Bio
before the Plan in all future filings that the Company makes with the SEC,
including this Report.

                                       16
```

```

RESULTS OF OPERATIONS

COMPARISON OF THE THREE MONTHS AND SIX MONTHS PERIODS ENDED JUNE 30, 2009 AND
2008 (IN THOUSANDS)

NexGen is a development stage company which has not yet generated any revenues
from operations, but which has operational costs related to our efforts to plan,
develop, construct and/or acquire biofuels business. These costs include legal
and professional costs, salaries, travel and other.

The legal and professional costs amounted to $17 for the three months ended June
30, 2009 compared to $138 for the three months ended June 30, 2008. The legal
and professional costs amounted to $28 for the six months ended June 30, 2009
compared to $361 for the six months ended June 30, 2008.

The salaries for the three months ended June 30, 2009 amounted to $0 compared to
$115 for the three months ended June 30, 2008. The salaries for the six months
ended June 30, 2009 amounted to $83 compared to $271 for the six months ended
June 30, 2008.

The travel expenses for the three months ended June 30, 2009 amounted to
$0compared to $24 for the three months ended June 30, 2008. The travel expenses
for the six months ended June 30, 2009 amounted to $3 compared to $95 for the
six months ended June 30, 2008. Travel costs are for travel in the U.S. and out
of the U.S. in connection with the land purchase options, the Purchase Agreement
during 2007 and, our efforts to raise funds during 2009.

During the three months ended June 30, 2009, we had $ 0 in compensation expenses
related to the issuance of shares and option shares to employees and a director,
compared to $59 compensation expenses for the comparable period of 2008. During
the six months ended June 30, 2009, we had $0 in compensation expenses related
to the issuance of shares and option shares to employees and a director,
compared to $534 compensation expenses for the comparable period of 2008.

Net loss for the three months ended June 30, 2009 amounted to $19 and $394 for
the three months ended June 30, 2008. Net loss for the six months ended June 30,
2009 amounted to $179 and $1,392 for the six months ended June 30, 2008.

LIQUIDITY AND CAPITAL RESOURCES (IN THOUSANDS)

The Company's working capital was a negative of $ 156 at June 30, 2009, compared
to a negative of $287 at June 30, 2008. Historically, our cash needs have been
satisfied primarily through proceeds from private placements of our equity
securities and related party advances. We expect to continue to be required to
raise capital in the future, but cannot guarantee that such financing activities
will be sufficient to fund our current and future projects and our ability to
meet our cash and working capital needs.

Net cash used in operating activities amounted to $(96) for the six months
period ended June 30, 2009 compared to $(1,047) net cash used in operating
activities for the six months ended June 30, 2008.

Cash provided by investing activities amounted to $0 for the six months period
ended June 30, 2009 compared to $167 used in investing activities in the six
months ended June 30, 2008.

Cash provided from financing activities amounted to $94 for the six months
period ended June 30, 2009 compared to $881for the six months ended June 30,
2008. Financing activities for both periods represent net cash received from the
Company's controlling shareholder for the development of NexGen's business.
Additionally, during the first quarter of fiscal 2008 we raised approximately
$225 through cash generated by the sale of stock via a private offering.

                                       17
```

```

We have an unsecured line of credit in the amount of $500 available through its
controlling shareholder. We believe these funds will be sufficient to fund our
current operations until we obtain the third-party financing to fund the first
phase of our business plan. However, additional funding may not be available
when required or it may not be available on favorable terms. Without adequate
funds, we may need to significantly reduce or refocus our plan of operations or
obtain funds through arrangements that may require us to relinquish rights to
certain or potential markets, either of which could have a material adverse
effect on our business, financial condition and results of operations. Failure
to secure additional financing in a timely manner and on favorable terms when
needed will have a material adverse effect on the Company's ability to continue
as a going concern, which contemplates the realization of assets and
satisfaction of liabilities in the normal course of business.

As of June 30, 2009, the Company was not subject to any off balance agreements,
other then the office lease agreement disclosed under Item 2 "Description of
Property" in our Form 10K.

ITEM 3. CONTROLS AND PROCEDURES

     (a)  Disclosure Controls and Procedures

          The Company performed an evaluation of the effectiveness of its
          disclosure controls and procedures (as defined in Rules 13a-15(e) and
          15d-15(e) of the Securities Exchange Act of 1934, as amended) as of
          the end of the period covered by this report. Based on the Company's
          evaluation, the Company's management, including the Chief Executive
          Officer and the principal Financial Officer, has concluded that the
          Company's disclosure controls and procedures as of the end of the
          period covered by this report were effective.

     (b)  Change in internal control over financial reporting. No change in the
          Company's internal control over financial reporting occurred during
          the Company's most recent fiscal quarter that has materially affected,
          or is reasonably likely to materially affect the Company's internal
          control over financial reporting

     (c)  Management believes that a controls system, no matter how well
          designed and operated cannot provide absolute assurance that the
          objectives of the controls system are met, and no evaluation of
          controls can provide absolute assurance that all control issues and
          instances of fraud, if any, within a company have been detected.

                                       18
```